Post-Market Surveillance and PMCF Under EU MDR: A Practical Guide

The EU Medical Device Regulation 2017/745 (EU MDR) introduced the most demanding post-market requirements ever applied to medical device manufacturers in Europe. Where the legacy Medical Device Directive (MDD) treated post-market surveillance as a largely administrative function, EU MDR transforms it into a continuous, data-driven clinical discipline that directly determines whether a device remains on the market and whether its certification is renewed.

At the heart of EU MDR's post-market framework are three interconnected obligations: the Post- Market Surveillance (PMS) system required by Article 83, the Post-Market Clinical Follow-Up (PMCF) plan required by Annex XIV Part B, and the Periodic Safety Update Report (PSUR) required by Article 86 for Class IIa, IIb, and Class III devices. Together, these obligations require manufacturers to collect, analyze, and act upon real-world clinical data throughout the entire commercial life of every device, updating their technical documentation and risk management files accordingly.

For many manufacturers, particularly small and mid-sized companies that marketed products under MDD with minimal post-market infrastructure, EU MDR's PMS requirements represent a fundamental transformation of how quality and regulatory functions must operate. This white paper provides a comprehensive, practitioner-oriented guide to understanding, designing, and operating a compliant EU MDR PMS system, with specific guidance on PMCF planning, PSUR structure, and the quality management infrastructure that makes sustained compliance achievable.

It concludes with an examination of how Cloudtheapp's validated quality management platform provides the operational backbone that medical device manufacturers need to meet EU MDR's post-market obligations without building a separate compliance infrastructure from scratch.

The Stakes of EU MDR PMS Non-Compliance Notified Bodies conducting EU MDR surveillance audits reported that PMS system deficiencies were the most common major non-conformity cited in 2023 and 2024, accounting for 41% of all major findings. Manufacturers that cannot demonstrate a functioning PMS system, including an active PMCF plan and a current PSUR, face suspension or withdrawal of their CE mark, effectively removing the device from the European market. For manufacturers whose EU revenue depends on CE certification, this is an existential compliance obligation.